E3S Web Conf.
Volume 292, 20212021 2nd International Conference on New Energy Technology and Industrial Development (NETID 2021)
|Number of page(s)||7|
|Section||Environmental Sustainable Development and Industrial Transformation|
|Published online||09 September 2021|
Major clinical advances of depression: now and future
1 The Bolles School, 7400 San Jose Blvd, Jacksonville, FL 32217, United States.
2 Long Island Lutheran Middle & High school, Glen Head, NY, 11545.
3 Saint Anthony's High School, South Huntington, NY, 11747, United States.
4 Shen Wai International School, Nanshan, Shenzhen, 518053, China.
† These authors contributed equally to this work.
* Corresponding author: email@example.com
Depression, as one of the largest influence disorders, needs more attention on its growing patients. Medicine treatment has been seeing as the major treatment for depression. As one of the most commonly used medicine, Selective Serotonin Reuptake Inhibitors (SSRIS) increases serotonin levels to treat depression effectively, and the data from clinical data prove its value. Furthermore, Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) and Monoamine Oxidase Inhibitors (MAOIs) treat depression by affecting at least one neurotransmitter, generally is chemical in the brain and digestive system. Other therapies were mostly as an auxiliary, such as psychological therapy, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), and Vagus Nerve Stimulation (VNS). These therapies often work effectively by stimulating neurotransmitters’ activity and increasing the activeness of the reward system. After new study and technology production, new development like ketamine can satisfy Individual Differences by more detailed inspection. Optogenetics in auxiliary treatment can be another way to increase the exactness of ECT and VNS after solving problems such as actual circuits in the whole network. In this review, we first focus mostly on drug treatments. We then summarize current information for other treatments and discuss the mechanisms that lead to in effect. Ultimately, we predict future development in the drug and optogenetics area. The previous study on depression treatment leads us a way to discover a future solution.
© The Authors, published by EDP Sciences, 2021
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.